Canaccord analyst Susan Anderson lowered the firm's price target on Perrigo to $17 from $20 and keeps a Buy rating on the shares. The firm said Management noted they ended 4Q25 and FY25 with share gains for both private label store brands and their key branded business, but saw softness in the infant nutrition business. It's been a challenging 2 years for the company primarily due to issues around the infant nutrition business. However, the rest of the business is performing well with distribution, contract, and share gains in a tough environment.
